The USFDA has conducted a surveillance inspection at the Zydus group’s API Unit 1, located at Ankleshwar in Gujarat. The inspection was conducted from March 10th to 14th, 2025. The inspection concluded with NIL observations.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.